Alex Karlsson-parra

MD, PhD, is the founder and Chief Scientific Officer of Immunicum. He has more than 30 years of experience in the scientific field of autoimmunity and transplantation immunity and has published more than 70 scientific articles. Dr. Karlsson-Parra and his scientific team at Immunicum have developed two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®. Since the raw material consists of white blood cells (activated DCs) from healthy donors, the vaccines can be mass-produced. The therapeutic cancer vaccine INTUVAX® is injected intratumorally and is currently being evaluated in a clinical Phase I/II-study in metastatic renal cell carcinoma. It utilizes each patient’s own unique tumor tissue as antigen source and is thus a completely personalized therapeutic cancer vaccine that can be mass-produced and subsequently stored as an ”off-the-shelf” vaccine in a frozen condition for long periods of time.